Breaking News

PharmaCell To Purchase TiGenix Production Facility

By Kristin Brooks | January 24, 2014

Expands cell therapy production, establishes long-term manufacturing agreement

PharmaCell B.V. a contract manufacturer for Cellular Therapies and Regenerative Medicine in Europe, has entered into an agreement with TiGenix N.V. to purchase its cell therapy production facility in Sittard-Geleen, The Netherlands. TiGenix is a European cell therapy company with a marketed product, ChondroCelect, for cartilage repair.
PharmaCell will acquire the facility, including its team of employees in production, QC, QA and other functions. ChondroCelect will continue to be manufactured at the site under a long-term agreement with PharmaCell.
In 2012, the Sittard-Geleen manufacturing facility successfully passed cGMP inspection by the Dutch authorities, and obtained approval from the EMA for the production of ChondroCelect. PharmaCell plans to produce other commercial and investigational cell therapy and regenerative medicine products at the site.
Alexander Vos, chief executive officer of PharmaCell B.V., said, “The new partnership with TiGenix is a further step forward to strengthen our business in support of the development of the cell therapy industry in Europe. PharmaCell and TiGenix have created a collaborative business model for cell therapeutics in general and for ChondroCelect in particular.”

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks